Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables: 2019-2025

Historic Receivables for Seres Therapeutics (MCRB) over the last 3 years, with Sep 2025 value amounting to $404,000.

  • Seres Therapeutics' Receivables was N/A to $404,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year change of. This contributed to the annual value of $17.6 million for FY2020, which is 455.88% up from last year.
  • Seres Therapeutics' Receivables amounted to $404,000 in Q3 2025, which was down 95.52% from $9.0 million recorded in Q1 2025.
  • In the past 5 years, Seres Therapeutics' Receivables ranged from a high of $9.0 million in Q1 2025 and a low of $404,000 during Q3 2025.
  • Moreover, its 1-year median value for Receivables was $4.7 million (2025), whereas its average is $4.7 million.
  • Examining YoY changes over the last 5 years, Seres Therapeutics' Receivables showed a top increase of 24.95% in 2021 and a maximum decrease of 63.16% in 2021.
  • Seres Therapeutics' Receivables (Quarterly) stood at $1.2 million in 2021, then followed by $404,000 in 2025.
  • Its Receivables was $404,000 in Q3 2025, compared to $9.0 million in Q1 2025 and $1.2 million in Q3 2021.